Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants

9 Sept 2023

Abstract excerpt

The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the emergence of new variants that are resistant to existing vaccines and therapeutic antibodies, has raised the need for novel strategies to combat the persistent global COVID-19 epidemic. In this study, a monoclonal anti-human angiotensin-converting enzyme 2 (hACE2) antibody, ch2H2, was isolated and humanized to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37689971
DOI: 10.1016/j.ymthe.2023.09.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variantsPMID 37689971Read ↗

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variantsSemantic proximity Read ↗

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blockerSemantic proximity Read ↗

ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus BlockerSemantic proximity Read ↗

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read ↗

Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infectionSemantic proximity Read ↗

Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitorsSemantic proximity Read ↗

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodiesSemantic proximity Read ↗

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsSemantic proximity Read ↗

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity Read ↗

DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTSSemantic proximity Read ↗

Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockadeSemantic proximity Read ↗

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.